Evidence map›Paper›PMID 36583054›Full record

ArticleFrontiers in microbiology2022

Synthesis and characterization of semisynthetic analogs of the antifungal occidiofungin.

Mengxin Geng, Nopakorn Hansanant, Shi-En Lu, Steve W Lockless, Ronald Shin, Ravi Orugunty, Leif Smith

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mengxin GengDepartment of Biology, Texas A&M University, College Station, TX, United States.
Nopakorn HansanantDepartment of Biology, Texas A&M University, College Station, TX, United States.
Shi-En LuDepartment of Biochemistry, Molecular Biology, Entomology and Plant Pathology, Mississippi State University, Mississippi State, MS, United States.
Steve W LocklessDepartment of Biology, Texas A&M University, College Station, TX, United States.
Ronald ShinCentral Alabama High-Field NMR Facility, Structural Biology Shared Facility, Cancer Center University of Alabama at Birmingham, Birmingham, AL, United States.
Ravi OruguntySano Chemicals Inc., Bryan, TX, United States.
Leif SmithDepartment of Biology, Texas A&M University, College Station, TX, United States.
Texas A&M University · USBryan College · USMississippi State University · USUniversity of Alabama at Birmingham · US

Funding

Preclinical Development of OCF001 for Treatment of Yeast InfectionsR42AI131792 · NIAID · SANO CHEMICALS, INC · PI SMITH, JAMES LEIF · 2019 to 2021
$2.9M
800 MHz NMR Spectrometer for the Central Alabama High-Field NMR FacilityS10RR022994 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KRISHNA, NEPALLI RAMA · 2009 to 2009
$2.0M
Lead Compound Discovery from Engineered Analogs of OccidiofunginR41AI131792 · NIAID · SANO CHEMICALS, INC · PI SMITH, JAMES LEIF · 2017 to 2017
$225k
NCRR NIH HHS S10 RR022994NIAID NIH HHS R41 AI131792NIAID NIH HHS R42 AI131792
6 · The paper itself

Abstract

Occidiofungin is a broad-spectrum antifungal compound produced by

Indexed as

antifungalCandidaNMRNRPSoccidiofunginsemisynthetic analog

Identifiers

PMID36583054
PMCPMC9792986
OpenAlexW4312138188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.